Rheumatoid arthritis and cardiovascular disease

被引：16
作者：
Wasko M.C.M. [1 ]
机构：
[1] Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA 15261
来源：
Current Rheumatology Reports | 2008年 / 10卷 / 5期
基金：
美国国家卫生研究院;
关键词：
Rheumatoid Arthritis; Rheumatoid Arthritis Patient; Rheumatol; Disease Activity Score; Subclinical Atherosclerosis;
D O I：
10.1007/s11926-008-0063-0
中图分类号：
学科分类号：
摘要：
An increased risk of cardiovascular events and subclinical atherosclerosis in patients with rheumatoid arthritis (RA) has been attributed to the inflammatory milieu associated with this chronic autoimmune disease and possibly to the independent effects of RA medications on risk. This review provides an update on the most recent epidemiologic studies documenting this relationship and noteworthy publications examining RA-related factors that could influence the role of traditional cardiovascular risk factors and expression of atherosclerotic disease in patients with RA. © Springer Science+Business Media, LLC 2008.
引用
收藏
页码：390 / 397
页数：7
相关论文
共 60 条
[21]  
Dessein P.H., Tobias M., Veller M.G., Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis, J Rheumatol, 33, pp. 2425-2432, (2006)
[22]  
McMahon M., Grossman J., FitzGerald J., Et al., Proin-flammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis, Arthritis Rheum, 54, pp. 2541-2549, (2006)
[23]  
Cesur M., Ozbalkan Z., Temel M.A., Karaastan Y., Ethnicity may be a reason for lipid changes and high Lp(a) levels in rheumatoid arthritis, Clin Rheumatol, 26, pp. 355-361, (2007)
[24]  
Georgiadis A.N., Papavasilious E.C., Lourida E.S., Et al., Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: Effect of early treatment-a prospective, controlled study, Arthritis Res Ther, 8, (2006)
[25]  
Lourida E.S., Georgiadis A.N., Papavasilious E.C., Et al., Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2, Arthritis Res Ther, 9, (2007)
[26]  
Charles-Schoeman C., Khanna D., Furst D.E., Et al., Effects of high-dose atorvastatin on anti-inflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: A pilot study, J Rheumatol, 34, pp. 1459-1464, (2007)
[27]  
dePalbo P., Dietrich T., Karlson E.W., Antioxidants and other novel cardiovascular risk factors in subjects with rheumatoid arthritis in a large population sample, Arthritis Rheum, 57, pp. 953-962, (2007)
[28]  
Hahn B.H., Grossman J., Chen W., McMahon M., The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: Roles of inflammation and dyslipidemia, J Autoimmun, 28, pp. 69-75, (2007)
[29]  
Wasko M.C., Hubert H.B., Lilngala V.B., Et al., Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis, JAMA, 298, pp. 187-193, (2007)
[30]  
La Montagna G., Cacciapuoati F., Buono R., Et al., Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis, Diabetes Vasc Dis Res, 4, pp. 130-135, (2007)
123456